Revvity Inc. (RVTY)

Revvity Inc. (RVTY) stock is trading near its 52-week high after reporting a Q2 beat with $1.41 EPS and $729.69 million revenue, despite a slight revenue decline year-over-year. The company's Q2 results set the tone for its FY 2026 guidance, aligning closely with analyst expectations. Despite its high valuation, driven by its core life sciences and diagnostics business, new institutional buying shows continued investor interest.

Revvity (RVTY) is experiencing significant options interest, particularly with its September 18, 2026 $50 put, indicating expectations for a major stock move. The stock has shown strong recent performance but is considered about 3% overvalued based on an analyst narrative, which projects a future increase in operating and net margins. However, a Discounted Cash Flow (DCF) model by Simply Wall St suggests the stock is currently undervalued by approximately 18% at $124.84 against a fair value of $153.02.

Revvity (RVTY) has seen a surge in options activity, with high implied volatility in its September 2026 $50 put options, indicating expectations for a significant stock movement. The stock has experienced strong recent momentum, but analysts present mixed views on its valuation, with one narrative suggesting it's 3.1% overvalued at $124.84 compared to a fair value of $121.07, while a discounted cash flow model suggests it is undervalued with a fair value of $153.02. Investors are encouraged to review the full picture and various valuation models to form their own thesis.

Revvity, Inc. director Alexis P. Michas reported a charitable donation of 285 shares of Revvity common stock from The Cayre and Alexis Michas Foundation Corp. to a nonprofit organization. The transaction, dated August 25, 2026, was a gift at no cost. Following the donation, the foundation indirectly holds 6,985 shares, while Michas directly owns 63,780 shares and indirectly holds 500 shares through a spouse's IRA.

Revvity (NYSE: RVTY) director Alexis P. Michas reported a bona fide gift of 285 shares of common stock from The Cayre and Alexis Michas Foundation Corp. to a charitable organization. Following this transaction, the foundation indirectly holds 6,985 shares, Michas directly holds 63,780 shares, and a spouse IRA indirectly holds 500 shares. Michas disclaims beneficial ownership of the foundation-held shares except for any pecuniary interest.